MedTrace Logo

SBRT/RT in Oligometastatic Stage IV NSCLC

NCT05647590 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-01-30

No results posted yet for this study

Summary

The core hypothesis to be tested is that the use of consolidative SBRT followed by maintenance chemotherapy in patients with less than or equal to 10 metastatic sites will improve progression-free survival (PFS) with acceptable toxicity compared to maintenance chemotherapy alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

PROCEDURE

Chemotherapy

3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)

PROCEDURE

Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)

* RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR) * SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks … maintenance

PROCEDURE

Maintenance chemotherapy

Maintenance chemotherapy will follow 3-6 weeks after RT.

Sponsors & Collaborators

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Tereza Paračková, MD · University Hospital Ostrava

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647590 on ClinicalTrials.gov